NCT02612285 2018-11-14
Study of SNX-5422 in TP53 Null Cancers
Esanex Inc.
Phase 2 Terminated
Clinical Trials
10 trialsNCT02063958 2018-07-30
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
Esanex Inc.
Phase 1 Completed
NCT02914327 2018-07-30
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
Esanex Inc.
Phase 1 Withdrawn
NCT00644072 2017-07-02
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01635712 2017-04-26
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
Esanex Inc.
Phase 1 Completed
NCT01848756 2017-02-09
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
Esanex Inc.
Phase 1/2 Terminated
NCT01851096 2016-08-16
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Esanex Inc.
Phase 1 Completed
NCT01611623 2013-04-02
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Esanex Inc.
Phase 1 Completed
NCT00506805 2012-05-28
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
Esanex Inc.
Phase 1 Completed
NCT00595686 2012-05-17
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Esanex Inc.
Phase 1 Completed